Pembrolizumab for the treatment of melanoma

被引：1

作者：

Kumar, Sanjeev Srinivas ^{[1
]}

McNeil, Catriona Mairi ^{[1
]}

机构：

[1] Chris OBrien Lifehouse, Dept Med Oncol, Camperdown, NSW 2050, Australia

来源：

EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2015年 / 8卷 / 05期

关键词：

immunotherapy; lambrolizumab; melanoma; pembrolizumab; pharmacology; TUMOR-IMMUNOTHERAPY; PD-L1; EXPRESSION; BRAIN METASTASES; PATIENTS PTS; OPEN-LABEL; IPILIMUMAB; ANTI-PD-1; THERAPY; SAFETY; NIVOLUMAB;

D O I：

10.1586/17512433.2015.1061430

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The immune system plays a vital role in regulating tumor growth, and the oncology community has witnessed an exciting resurgence in clinical research to develop effective immunotherapeutic strategies. The utility of these strategies in advanced melanoma has been at the forefront of these developments. In particular, blockade of programmed cell death protein 1 (PD-1) in advanced melanoma has proven to be a most promising new anticancer strategy. Pembrolizumab is a humanized IgG4 anti-PD-1 antibody that exerts its anti-tumor effect through blocking the interaction of the immune inhibitory molecule PD-1 with its ligands. Its effect has been most convincingly demonstrated in the setting of advanced melanoma, with growing evidence of clinical responses across a broad spectrum of other solid and hematological malignancies.

引用

页码：515 / 527

页数：13

共 56 条

[1] Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. [J].

Atkins, Michael B. ;

Reiney, Ragini ;

Sznol, Kudchadkar Mario ;

McDermott, David F. ;

Lotem, Michal ;

Schachter, Jacob ;

Wolchok, Jedd D. ;

Urba, Walter John ;

Kuzel, Timothy ;

Schuchter, Lynn Mara ;

Slingluff, Craig L. ;

Ernstoff, Marc S. ;

Fay, Joseph W. ;

Friedlander, Philip Adam ;

Gajewski, Thomas ;

Zarour, Hassane M. ;

Rotem-Yehudar, Rinat ;

Sosman, Jeffrey Alan .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[2] Final Version of 2009 AJCC Melanoma Staging and Classification [J].

Balch, Charles M. ;

Gershenwald, Jeffrey E. ;

Soong, Seng-jaw ;

Thompson, John F. ;

Atkins, Michael B. ;

Byrd, David R. ;

Buzaid, Antonio C. ;

Cochran, Alistair J. ;

Coit, Daniel G. ;

Ding, Shouluan ;

Eggermont, Alexander M. ;

Flaherty, Keith T. ;

Gimotty, Phyllis A. ;

Kirkwood, John M. ;

McMasters, Kelly M. ;

Mihm, Martin C., Jr. ;

Morton, Donald L. ;

Ross, Merrick I. ;

Sober, Arthur J. ;

Sondak, Vernon K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6199-6206

[3] Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion [J].

Blank, Christian ;

Mackensen, Andreas .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (05) :739-745

[4] Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. [J].

Brahmer, Julie R. ;

Rizvi, Naiyer A. ;

Lutzky, Jose ;

Khleif, Samir ;

Blake-Haskins, Andy ;

Li, Xia ;

Robbins, Paul B. ;

Vasselli, Jim ;

Ibrahim, Ramy A. ;

Antonia, Scott Joseph .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[5] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[6] PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells [J].

Cai, GF ;

Karni, A ;

Oliveira, EML ;

Weiner, HL ;

Hafler, DA ;

Freeman, GJ .

CELLULAR IMMUNOLOGY, 2004, 230 (02) :89-98

[7]

Carlino M., 2010, PIGM CELL MELANOMA R, V23, P874

[8] Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475) [J].

Daud, A. ;

Hamid, O. ;

Robert, C. ;

Hodi, F. S. ;

Wolchok, J. D. ;

Hwu, W. J. ;

Weber, J. S. ;

Kefford, R. ;

Hersey, P. ;

Joshua, A. M. ;

Joseph, R. ;

Gangadhar, T. C. ;

Dronca, R. ;

Patnaik, A. ;

Zarour, H. ;

Gerigich, K. ;

Lunceford, J. ;

Emacipator, K. ;

Dolled-Filhart, M. ;

Li, X. ;

Kang, P. ;

Ebbinghaus, S. ;

Ribas, A. .

EUROPEAN JOURNAL OF CANCER, 2014, 50 :48-49

[9]

DELAMONTE SM, 1983, CANCER RES, V43, P3427

[10] Mechanism of Action of Immunotherapy [J].

Disis, Mary L. .

SEMINARS IN ONCOLOGY, 2014, 41 :S3-S13

← 1 2 3 4 5 6 →